This is the way I see it - The stock was a good opportunity for those of us who go in really early. You can read my previous posts and I had almost 100K shares between 0.44 & 0.51 plus almost 400 calls spread between March (300 contracts), June (100) at an average of 0.125 cents. I sold 75% of my position between 0.88 & 1.03 plus half my march options at 0.55. So I made a lot of money. Now for you got in just during the run up and did not sell well is a good opportunity to average down. Bpax has multiple catalysts coming up this year to allow for the PPS to increase significantly. These are plays where you have to get in early - before everybody else shows up - At least 2 months in advance in my opinion. I am now looking to increase my June calls heavily plus get back in probably at 0.75. While I believe Bio-T gel adds confidence to the company's ability to secure partners and get products approved, I do not think it should have a major impact. Why? Because Bpax will only get 1.5M in an upfront payment and some royalties down the road. Really not much to write home about. However, the true value and major catalyst is Libigel which does not have a partner yet and the vaccine data. Those are the major scorers here. Nah sayers will keep on with the Libigel is dead tune, but of course, that is tied to an agenda. I am looking forward to the vaccine data as well. And of course there is the acquirer or acquiree option on the table. GLTA
